Carolyn Amole is the Vice President of HIV, Hepatitis, and Tuberculosis, leading CHAI’s efforts globally and across 20+ countries to expand access to life-saving products. Over her 16-year tenure at CHAI, she has pioneered new product introduction approaches and market shaping strategies that have transformed how health innovations reach people in low- and middle-income countries.

Carolyn steered CHAI’s role in the global introduction of tenofovir/lamivudine/dolutegravir (TLD), which now reaches more than 24 million people worldwide and has generated over $1 billion in treatment cost savings. She led the development of CHAI’s new product introduction toolkit (newhivdrugs.org) and pioneered the organization’s influential HIV market reports and market impact memos. Carolyn was instrumental in establishing CHAI’s partnerships with communities of people living with HIV, ensuring lived experience informs program strategy and implementation.

Previously, she led CHAI’s global market intelligence and country support teams while based in South Africa. Prior to joining CHAI, she worked in management consulting and she holds an A.B. in Government from Harvard.